Wanted: smarter reps, says survey

Share this article:
A snap survey of physicians found a yearning for smarter sales reps who know their disease states back and forth and can use clinical studies in their details.

The Sermo survey, commissioned by Publicis Selling Solutions Group and titled What Physicians Want, was completed by 208 practitioners. Of those respondents, 51% said they want reps with more education, training and experience, while 87% said they wanted to see greater use of clinical studies and evidence-based medicine in their interactions with reps.

They want to see fewer reps in their practices (90%), fewer “mirrored” or “pod” sales teams (72%) and fewer traditional primary care reps (69%), but want more “customer service representatives (77%)” doing lit and sample drops and more clinical health educators to address compliance and adherence problems (73%). They were also keen on specialty reps, with 60% of respondents saying they'd like to see more of them.

On communications from industry, respondents want more product and disease awareness websites targeted to professionals, as well as more industry-sponsored CME (78%) and more industry-sponsored peer-to-peer education and consultation (72%).
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...